Business
Result of Annual General Meeting
Cardiogeni PLC announced that all resolutions were passed at its Annual General Meeting held on December 31, 2025. The company, focused on novel heart regeneration medicines, has seen its lead product, CLXR-001, successfully complete an EU Phase II trial with statistically significant improvements in heart function and quality of life, and has begun dosing patients in a new randomized controlled trial with interim data expected within 24 months. Disclaimer*
About this update from Cardiogeni Plc
[{"type":"text","content":"\n\n31 December 2025\nCardiogeni PLC\n(\"Cardiogeni\" or the \"Company\")\n \nResults of Annual General Meeting\n \nCardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines, is pleased to announce that at the Company's Annual General Meeting (\"AGM\") held earlier today, all resolutions proposed were duly passed.\n \n \nENDS\nThe directors of Cardiogeni accept responsibility for this announcement.\n\n\nFor further information please contact:\n \n \n\n\n\n\nCardiogeni PLC\n\n\n\n\nDr Darrin M Disley, Executive Chairman\nAjan Reginald, Executive Officer\n\n\nVia First Sentinel\n\n\n\n\n \nFirst Sentinel Corporate Finance Limited, Corporate Adviser\n\n\n\n\nBrian Stockbridge\n\n\n+44 (0) 7858 888007\n\n\n\n\n \nSP Angel Corporate Finance LLP, Corporate Broker\n\n\n\n\nDavid Hignell\nVadim Alexandre\nDevik Mehta\n\n\n +44 20 3470 0470\n\n\n\n\n \n \n \n\n \n \nAbout Cardiogeni\n \nFounded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a specific therapeutic function.\n \nThe Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor Sir Martin Evans and the platform along with the pipeline of medicines in development are protected by a portfolio of ~100 international patents and trademarks.\n \nCLXR-001 targets heart failure which will affect 1 in 4 people in their lifetime and is not reversible or curable. CLXR-001 consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration whose mechanism of action is to regenerate damaged heart tissue and restoration of improved heart function improving both the life expectancy and quality of life of patients.\n \nCLXR-001 targets the cardiac market niche of CABG surgery with ~400,000 patients per year in the US alone. The Group's two follow-on produ...